Welcome to our dedicated page for SRRA news (Ticker: SRRA), a resource for investors and traders seeking the latest updates and insights on SRRA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SRRA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SRRA's position in the market.
Sierra Oncology (SRRA) has granted a stock option to a new employee, approved by the Compensation Committee under its 2018 Equity Inducement Plan. The employee can purchase 32,000 shares at an exercise price of $19.12 per share, equivalent to the closing price on the grant date. The option will vest 25% on the first anniversary of employment, with the remaining 75% vesting monthly over the following three years. Sierra Oncology focuses on delivering targeted therapies for rare cancers and aims to transform cancer treatment through innovative approaches.
Sierra Oncology (SRRA) announced the granting of a stock option to a new employee under its 2018 Equity Inducement Plan. The stock option includes 33,000 shares at an exercise price of $18.70, equal to the stock's closing price on the grant date. The option will vest 25% after one year, with the remainder vesting in monthly installments over three years, contingent upon continued employment. This plan complies with NASDAQ Listing Rule 5635(c)(4) and is part of Sierra's strategy to attract talent to support its focus on rare cancer treatments.
Sierra Oncology, Inc. (NASDAQ: SRRA) has completed enrollment for its pivotal Phase 3 MOMENTUM clinical trial of momelotinib in myelofibrosis patients. The trial exceeded its target, enrolling 195 patients across 21 countries. Topline data is expected in Q1 2022, with a New Drug Application (NDA) filing planned for H2 2022, pending positive results. CEO Stephen Dilly emphasized the trial's significance and the urgency for new treatment options. Momelotinib is a selective inhibitor targeting JAK1, JAK2, and ACVR1/ALK2, designed for symptomatic and anemic patients.
Sierra Oncology, Inc. (SRRA) announced an analyst and investor event set for June 21, 2021, at 4:30 pm ET. The event will feature leading myelofibrosis experts discussing the latest data on momelotinib, a potential treatment for myelofibrosis. Top-line data from the ongoing MOMENTUM clinical trial is expected in Q1 2022, with the FDA having granted Fast Track designation for momelotinib. This strategic event aims to enhance investor awareness around this promising therapy.
Sierra Oncology announced positive findings regarding its drug momelotinib at the EHA Annual Meeting. Data highlights that achieving transfusion independence (TI) at Week 24 correlates with improved overall survival in myelofibrosis patients. For JAKi-naïve patients, those who responded to momelotinib exhibited a three-year overall survival rate of 80%, significantly higher than the 50% for non-responders. Additionally, momelotinib demonstrated superior TI rates compared to ruxolitinib across various patient subsets. These findings may influence treatment decisions for myelofibrosis.
Sierra Oncology (SRRA) has appointed Georgia Erbez and Christy Oliger to its Board of Directors, strengthening its strategic and financial leadership as it prepares for the commercialization of momelotinib. Both bring extensive experience from reputable biotech and pharmaceutical companies. Erbez, currently CFO at Harpoon Therapeutics, has a strong background in finance within the biotech sector. Oliger, previously Senior VP at Genentech, has significant experience in oncology. This move is expected to enhance Sierra's operations as it aims to meet unmet needs in the myelofibrosis community.
Sierra Oncology, Inc. (SRRA), a biopharmaceutical company focused on targeted therapies for rare cancers, will participate in the 2021 Jefferies Healthcare Conference from June 1-4, 2021. CEO Stephen Dilly will present an overview of the company on June 3, 2021, from 1:30 to 1:55 pm ET. The presentation will be webcast live, with a replay available later on the company’s website. Sierra Oncology is dedicated to identifying compounds that effectively target the root causes of cancer and aims to transform the treatment landscape, although risks regarding funding and clinical development remain.
Sierra Oncology (SRRA) granted a stock option to a new employee under the 2018 Equity Inducement Plan. The employee received options for 39,000 shares with an exercise price of $17.79, equal to the stock's closing price at grant. The vesting schedule includes 25% vesting on the first anniversary and the remaining 75% over 36 months, contingent on continued employment. This plan adheres to NASDAQ Listing Rule 5635(c)(4), aimed at attracting talent crucial for the company's focus on targeted therapies for rare cancers.
Sierra Oncology (SRRA) announced the acceptance of three abstracts for the 2021 ASCO Annual Meeting, focusing on momelotinib for myelofibrosis treatment. One poster by Dr. Ruben Mesa will discuss transfusion independence and its association with improved overall survival in patients. Previous data from the SIMPLIFY studies show that momelotinib-treated patients have better survival rates compared to ruxolitinib. Additional abstracts will emphasize momelotinib's effectiveness in improving transfusion independence and symptom management in myelofibrosis patients.
Sierra Oncology, Inc. (SRRA) announced that new analyses from the SIMPLIFY-1 and SIMPLIFY-2 studies of momelotinib will be presented at the European Hematology Association Annual Meeting. The oral presentation will focus on findings indicating a significant association between transfusion independence at Week 24 and improved overall survival for myelofibrosis patients. The data suggest higher transfusion independence rates in patients treated with momelotinib. Presentations will occur virtually on June 11, 2021, showcasing the potential long-term benefits of momelotinib, particularly in JAKi-naïve patients.
FAQ
What is the market cap of SRRA (SRRA)?
